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A BS T R AC T
BACKGROUND

Options for mechanical circulatory support as a bridge to heart transplantation in
children with severe heart failure are limited.
METHODS

We conducted a prospective, single-group trial of a ventricular assist device designed
specifically for children as a bridge to heart transplantation. Patients 16 years of age
or younger were divided into two cohorts according to body-surface area (cohort 1,
<0.7 m2; cohort 2, 0.7 to <1.5 m2), with 24 patients in each group. Survival in the
two cohorts receiving mechanical support (with data censored at the time of transplantation or weaning from the device owing to recovery) was compared with survival
in two propensity-score–matched historical control groups (one for each cohort)
undergoing extracorporeal membrane oxygenation (ECMO).
RESULTS

For participants in cohort 1, the median survival time had not been reached at 174 days,
whereas in the matched ECMO group, the median survival was 13 days (P<0.001 by the
log-rank test). For participants in cohort 2 and the matched ECMO group, the median
survival was 144 days and 10 days, respectively (P<0.001 by the log-rank test). Serious
adverse events in cohort 1 and cohort 2 included major bleeding (in 42% and 50%
of patients, respectively), infection (in 63% and 50%), and stroke (in 29% and 29%).
CONCLUSIONS

Our trial showed that survival rates were significantly higher with the ventricular
assist device than with ECMO. Serious adverse events, including infection, stroke,
and bleeding, occurred in a majority of study participants. (Funded by Berlin Heart
and the Food and Drug Administration Office of Orphan Product Development;
ClinicalTrials.gov number, NCT00583661.)
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S

ystolic heart failure causes 280,000
deaths in adults annually in the United
States.1 Heart failure is much less common
among children than among adults, but it is highly lethal, with 46% of children with heart failure
dying or undergoing transplantation within 5 years
after diagnosis, according to one estimate.2 The
survival rate among children after heart transplantation is estimated at 83% at 3 years,3,4 but the
limited availability of donor hearts for children
prolongs the waiting period,5 resulting in a high
rate of death among children on waiting lists.6-8
Options for mechanical circulatory support as
a bridge to transplantation are limited for children. The mainstay of support for small children
has been extracorporeal membrane oxygenation
(ECMO). The effective period of support with
ECMO is typically limited to only 10 to 20 days
before serious complications ensue, such as bleeding and major organ-system failure, which often
preclude transplantation. The short duration of
support afforded by ECMO is often inadequate,
considering the current waiting times (a median
of 119 days for all infants in 20085). As a result,
only 40 to 60% of children requiring support with
ECMO survive long enough to undergo heart transplantation.9
The Excor Pediatric ventricular assist device
(Berlin Heart) is a paracorporeal, pneumatically
driven, pulsatile-flow mechanical circulatorysupport device available in a wide range of sizes.
We conducted a prospective study to evaluate this
device as bridge therapy in children who were on
waiting lists for orthotopic heart transplantation.

ME THODS
STUDY DESIGN

In this prospective, multicenter, single-group cohort study,10 we compared children who underwent
implantation of the Excor Pediatric ventricular
assist device as a bridge to transplantation with a
historical control group of children who received
circulatory support with ECMO. Seventeen pediatric cardiac centers in the United States and Canada
participated in the trial (see the Supplementary
Appendix, available with the full text of this article at NEJM.org, for a list of study sites and investigators).
The study was designed by the principal investigators and by clinical experts in pediatric trial
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design, hematology, and neurology in collaboration with the sponsor, Berlin Heart, and the Food
and Drug Administration. Data were gathered by
study coordinators at each site and were analyzed
by the sponsor and independent academic statisticians in collaboration with the study investigators.
The investigators had full access to the data. Data
monitoring was performed by a contract research
organization (Alquest). Data confidentiality was
required by contractual agreement between each
study site and the sponsor. The decision to submit
the manuscript for publication was made by members of the publication committee (see the Supplementary Appendix) and the sponsor. All authors
participated in writing, revising, and reviewing the
manuscript. The academic authors and the authors
who are employees of the sponsor vouch for the
accuracy and completeness of the data and analysis and the fidelity of the study to the trial protocol. The study protocol (available at NEJM.org)
was approved by the institutional review board at
each participating center, and written informed
consent was provided by a parent or legal guardian for all study participants.
PARTICIPANT SELECTION

Children were eligible for the study if they were
16 years of age or younger, weighed between 3 and
60 kg, had two-ventricle circulation, had severe
heart failure despite optimized medical treatment,
and were on a waiting list for cardiac transplantation. Children who had already been receiving
another form of mechanical circulatory support
were allowed to participate, except for those who
had received circulatory support with ECMO for
10 days or more (see Table S1 in the Supplementary Appendix for a complete list of inclusion and
exclusion criteria). After enrollment, participants
were stratified according to body-surface area.
Cohort 1 included all participants with a bodysurface area of less than 0.7 m2, and cohort 2 all
participants with a body-surface area of at least
0.7 m2 but less than 1.5 m2.
STUDY PROTOCOL

Each participant underwent surgical implantation
of an Excor Pediatric ventricular assist device, the
size of which was chosen on the basis of age
and body weight. Devices with stroke volumes of
10, 25, 30, 50, and 60 ml were available (Fig. S1
and S2 in the Supplementary Appendix).11 Par-
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ticipants underwent implantation of one device
in the left ventricle only (left ventricular assist) or
of devices in both left and right ventricles (biventricular assist) on the basis of an algorithm developed to predict right-heart performance at the
time of surgery and at the clinical discretion of the
surgeon performing the implantation.10 Standardized antithrombotic therapy was recommended
(Fig. S3 in the Supplementary Appendix).10 After
postoperative recovery, patients in stable condition were typically treated with aspirin, dipyrid
amole, and either warfarin or enoxaparin.
Study data were collected within 48 hours
before device implantation; at implantation; at 1,
2, 4, and 6 weeks; at 3 and 6 months; and every
3 months thereafter while the child received cir-
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culatory support with the ventricular assist device.
Participants who were deemed to be acceptable
candidates for a heart transplant after implantation of the device underwent transplantation if
and when a suitable donor organ became available. Participants with signs of substantial ventricular recovery were weaned from the ventricular assist device, meaning that support with the
device was gradually discontinued, and the pump
surgically explanted.
SELECTION OF HISTORICAL CONTROL GROUP

A historical control group of children receiving circulatory support with ECMO was selected from the
Extracorporeal Life Support Organization (ELSO)
registry. The ELSO registry is a multicenter, vol-

Table 1. Characteristics of the Study Participants.*
ECMO Matched
Group for
VAD Cohort 1
Cohort 1
(N = 24)
(N = 48)†
P Value‡

Variable

ECMO Matched
Group for
VAD Cohort 2
Cohort 2
(N = 24)
(N = 48)†
P Value‡

Age — mo§
Median

11.7

10.6

Range

2.6–45.6

0.1–112.3

0.53

Median

9.2

8.8

Range

3.6–13.6

3.1–27.0

111.2

138.7

50.8–191.8

1.8–188.6

30.7

36.0

16.0–58.1

4.0–59.0

0.96

Weight — kg§
0.79

Primary diagnosis — no. (%)§

0.32

0.51

Congenital heart disease

3 (12)

8 (17)

6 (25)

Coronary artery disease

0

0

0

Dilated cardiomyopathy or myocarditis

19 (79)

39 (81)

17 (71)

15 (31)
1 (2)
31 (65)

Hypertrophic cardiomyopathy

1 (4)

0

0

0

Restrictive cardiomyopathy

1 (4)

0

1 (4)

0

Valvular heart disease

0

1 (2)

0.96

0

1 (2)

Preoperative mechanical ventilation — no. (%)§

20 (83)

36 (75)

0.42

11 (46)

26 (54)

0.50

Preoperative inotrope infusion — no. (%)§

22 (92)

43 (90)

0.78

21 (88)

40 (83)

0.64

7 (29)

14 (29)

1.00

5 (21)

13 (27)

0.56

Preoperative cardiac arrest — no. (%)§
2

Body-surface area — m
Median

0.44

1.08

Range

0.23–0.62

0.71–1.66‖

12 (50)

13 (54)

1

11 (46)

13 (54)

2

13 (54)

11 (46)

Male sex — no. (%)
INTERMACS profile status at implantation —
no. (%)¶

534

n engl j med 367;6

nejm.org

august 9, 2012

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 26, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

Prospective Trial of a Pediatric Ventricular Assist Device

Table 1. (Continued.)
ECMO Matched
Group for
VAD Cohort 1
Cohort 1
(N = 24)
(N = 48)†
P Value‡

Variable

ECMO Matched
Group for
VAD Cohort 2
Cohort 2
(N = 24)
(N = 48)†
P Value‡

Preoperative ECMO — no. (%)

6 (25)

8 (33)

Preoperative centrifugal VAD — no. (%)

2 (8)

0

Type of implant — no. (%)
LVAD

17 (71)

14 (58)

BiVAD

7 (29)

10 (42)

Closure of intracardiac shunt at implantation
— no. (%)

7 (29)

3 (12)

Valve repair or replacement at implantation
— no. (%)

2 (8)

4 (17)

Time required for cardiopulmonary bypass
— min

185±49

176±52

* Plus–minus values are means ±SD. BiVAD denotes biventricular assist device, ECMO extracorporeal membrane oxygenation, LVAD left ventricular assist device, and VAD ventricular assist device.
† The correlation coefficient for the matched propensity scores was 0.97 for cohort 1 (P<0.001) and 0.96 for cohort 2 (P<0.001).
‡ P values for comparison of the ventricular-assist cohorts with the propensity-score–matched ECMO groups were obtained with the t-test or
chi-square test.
§ These variables were used in the propensity-score analysis to match historical control groups from the Extracorporeal Life Support Organization
(ELSO) database with the ventricular-assist cohorts.
¶ According to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS),13 a profile status of 1 indicates critical
cardiogenic shock, and 2 progressive decline.
‖ One participant had a body-surface area of 1.66 m2, which was outside the eligibility-criteria specifications; a protocol deviation was documented for this occurrence.

untary database that enrolls patients who receive
ECMO support. A propensity-score analysis was
used to match each participant who received a
ventricular assist device to two children who had
received support with ECMO (selected from the
ELSO database). The propensity-score matching
was performed separately and independently for
each of the two cohorts. Details regarding the
ELSO database and the propensity-score matching are provided in the Supplementary Appendix.
STUDY OUTCOMES

The primary efficacy end point was defined differently for the ventricular-assist and ECMO groups.
For the ventricular-assist group, the primary end
point was the time to death or weaning from the
device with an unacceptable neurologic outcome.
Death was defined as any death occurring while
the child required support with the device or death
within 30 days after weaning from the device or
before hospital discharge, whichever was longer.
An unacceptable neurologic outcome was defined
as either coma or the presence of profound sensory,

n engl j med 367;6

motor, language, or cognitive impairment as assessed with the Pediatric Stroke Outcome Measure12 (see the Supplementary Appendix for details
of the neurologic assessments and the Pediatric
Stroke Outcome Measure). Data from participants
who underwent heart transplantation or who had
ventricular recovery with uneventful weaning from
the device were censored at the time of transplantation or weaning.
For the ECMO group, the primary end point
was only the time to death (as defined above),
because data on neurologic status were not available in the ELSO database. Data from patients who
underwent device explantation and survived for at
least 30 days were censored; the ELSO database
does not specify whether such explants were due
to recovery or transplantation.
In a secondary outcome assessment, outcome
events were classified for a competing-risk analysis. For the ventricular-assist group, four mutually
exclusive outcome events were tracked: death during receipt of circulatory support with the device;
heart transplantation; failure of weaning (defined
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as death or an unacceptable neurologic outcome,
as defined above, within 30 days after weaning or
before discharge from the hospital, whichever was
longer); and successful weaning (defined as weaning from the device without death or an unacceptable neurologic outcome within 30 days after
weaning or before discharge from the hospital).
For the ECMO group, three mutually exclusive outcome events were tracked: death during receipt of
support with ECMO, death within 30 days after
weaning from the device, and removal of the device (without death within 30 days after device removal). For both groups, children who had not yet
had any of these specific outcome events were classified as being alive and receiving support with the
device.
Additional data were collected for the ventricular-assist group. Data on device performance
(e.g., function of the driver system and the drive
lines, system failures, systolic and diastolic pressures, and stroke rate) were recorded routinely
while participants receiving circulatory support
with the device. Functional status was assessed at
each time point by determining whether the participant was sedated, intubated, eating, or ambulating. Information about functional status is provided in the Supplementary Appendix. Adverse
events were documented throughout the study
according to standardized definitions from the
Interagency Registry for Mechanically Assisted
Circulatory Support13 (Table S3 in the Supplementary Appendix).
A clinical events committee adjudicated all adverse events, the neurologic status of patients
who were considered to be weaned from the device owing to recovery, and deaths. A data and
safety monitoring committee evaluated the study
data every 6 months to ensure the safety of the
participants and the integrity of the study (see
the Supplementary Appendix).

survival with the ventricular assist device would be
significantly longer than survival with ECMO.
All comparisons between the ventricular-assist
and ECMO groups were performed on an intention-to-treat basis. Cumulative event rates were
calculated according to the Kaplan–Meier method.
For the ventricular-assist group, the time to an
event was measured from the time of implantation
of the ventricular assist device, regardless of
whether another form of mechanical support had
been in use before implantation. For the ECMO
group, the time to an event was measured from
the time of implantation of the ECMO device. The
between-group difference in the time to the occurrence of the primary end point was assessed
by means of the log-rank test within each of the
two study cohorts. The duration of support with
the device was compared with the use of the
Wilcoxon median two-sample test.
The primary efficacy outcome was also evaluated with the use of a competing-risk analysis. The
proportion of participants having each of the competing outcomes at each time point was plotted.
Outcomes at 30 days and at the end of device support for the participant who received support for
the longest time were compared between groups
with the use of chi-square tests.
The primary safety end point was calculated as
the number of serious adverse events per day during circulatory support with the ventricular assist
device. A Poisson exact confidence interval was
calculated, and the critical-value method was used
for significance testing. Success was prospectively
defined as less than 0.25 events per day for the
upper bound of the 95% Poisson exact confidence
interval. A two-tailed Fisher’s exact test was used
to compare the proportion of participants in each
functional-status category at each time point with
the proportion in each category before the devices
were implanted.
All reported P values are two-sided. A P value of
STATISTICAL ANALYSIS
less than 0.05 was considered to indicate statistiWe estimated that the median time to the primary cal significance, without adjustment for multiple
end point for participants with the ventricular assist comparisons.
device would be 100 days, and the median time to
the primary end point for the propensity-score–
R E SULT S
matched control group of children receiving support with ECMO would be 5 days. On the basis of STUDY PARTICIPANTS
these assumptions, we calculated that the inclusion We enrolled 48 children, 24 in each cohort, in the
of 24 participants in each ventricular-assist cohort trial between May 2007 and December 2010. In
would provide more than 99% power, with a two- cohort 1, the median age was 1 year and the mesided alpha level of 0.05, to test the hypothesis that dian weight was 9 kg. In cohort 2, the median age
536
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For children in cohort 1, the median duration of
support with the ventricular assist device was
28 days, as compared with 5 days for the matched
ECMO group (P<0.001 by the Wilcoxon median
two-sample test). The longest duration of support with the device in each of these two groups
was 174 days and 21 days, respectively. For children in cohort 2, the median duration of support
with the device was 43 days, as compared with
5 days for the matched ECMO group (P<0.001 by
the Wilcoxon median two-sample test). The longest duration of support with the device in each
of these two groups was 192 days and 28 days,
respectively.
Among participants in cohort 1, the median
time to the primary end point had not yet been
reached at 174 days. In contrast, the median time
to the primary end point in the matched ECMO
group was 13 days (P<0.001 by the log-rank test)
(Fig. 1A). Among participants in cohort 2, the median time to the primary end point was 144 days,
as compared with 10 days in the matched ECMO
group (P<0.001 by the log-rank test) (Fig. 1B).
Competing-outcome analyses are shown in
Figures 2 and 3. In the ECMO group for cohort
1, at 21 days, 25% of the patients had died, and
none were alive and still receiving support with
ECMO (Fig. 2A). In the ECMO group for cohort
2, at 30 days, 33% of the patients had died, and
none were alive and still receiving support
with ECMO (Fig. 2B). In contrast, in cohort 1, at
174 days, 88% of the patients had undergone
successful transplantation and 12% had died or
had an unacceptable neurologic outcome after
weaning from the device (Fig. 3A). In cohort 2,
at 192 days, 92% of the patients had undergone
successful transplantation or had been weaned
from the device, and 8% had died (Fig. 3B).
Overall, 88% of the participants in cohort 1 and
92% of those in cohort 2 survived to undergo
either heart transplantation or weaning from the
device (Table 2).
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Days after Implantation

B Freedom from Primary End Point, Cohort 2
100

Cohort 2

90
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Survival (%)

was 9 years and the median weight was 31 kg. In
both cohorts, the cause of cardiac failure in most
participants was cardiomyopathy or myocarditis,
with a much smaller proportion having congenital heart disease (Table 1). The propensity-score–
matching process resulted in statistically wellmatched control groups (Table 1, and Table S2 in
the Supplementary Appendix).

60
50
40
30
ECMO group

20
10
0

P<0.001 by log-rank test
0

20

40

60

80

100

120

140

160

180

Days after Implantation

Figure 1. Kaplan–Meier Estimates of Freedom from the Primary End Point
for Patients Who Received a Ventricular Assist Device and for Matched
Control Groups of Children Who Received Support with Extracorporeal
Membrane Oxygenation (ECMO).
Panels A and B show the data from cohorts 1 and 2, respectively, as compared
with data from their propensity-score–matched control groups. For both ventricular-assist cohorts, the primary end point was the time to death or weaning
from the device with an unacceptable neurologic outcome. Death was defined
as any death occurring while the child required support with the device, or any
death occurring within 30 days after weaning from the device or before discharge from the hospital, whichever was longer. An unacceptable neurologic
outcome was defined as either coma or the presence of profound sensory, motor, language, or cognitive impairment as assessed with the Pediatric Stroke
Outcome Measure12 (see the Supplementary Appendix). Data from participants who underwent heart transplantation or who had ventricular recovery
with uneventful weaning were censored at the time of transplantation or weaning. For the ECMO groups, the primary end point was only the time to death
(as defined above), because data on neurologic status were not available in the
Extracorporeal Life Support Organization (ELSO) database. Data from patients
who underwent device explantation and survived for at least 30 days were censored; the ELSO database does not specify whether such explants were performed because of recovery or transplantation. Each tick mark represents an
event, and I bars indicate asymmetric confidence intervals equivalent to 1 SE.
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Figure 2. Competing-Outcomes Analysis of the ECMO
Groups.
Three mutually exclusive outcome events were tracked
for this analysis: death occurring while the child was
receiving circulatory support with ECMO, death within
30 days after weaning from the device, and device removal
(without death within 30 days). Children who had not
yet had any of these specific outcome events were classified as being alive and receiving circulatory support.

ADVERSE EVENTS

The rate of serious adverse events in cohort 1 was
0.07 events per patient-day (95% confidence interval [CI], 0.06 to 0.08), and in cohort 2, the rate
was 0.08 events per patient-day (95% CI, 0.06 to
0.09). The upper bounds of the 95% confidence
intervals were both below the prospectively set
criterion for success of 0.25.
The most common serious adverse events
were major bleeding (in 42% of participants in
cohort 1 and in 50% of those in cohort 2), infection (in 63% and 50%, respectively), stroke (in
29% and 29%), and hypertension (in 50% and
33%). More details regarding deaths and adverse
neurologic outcomes, as well as a table of
adverse events (Table S7 in the Supplementary
Appendix), are provided in the Supplementary Appendix.
Forty-six pump changes occurred in cohorts
1 and 2 combined. Thrombus formation in the
device was identified as the reason for 43 of
these pump changes. Pump changes were required in three participants for whom no thrombus in the device was identified: one participant
had multiple infarcts on computed tomography
of the head, one had a neurologic event, and one
had positive fungal blood cultures.

Transplantation, 87.5

90

0

of

n engl j med 367;6

Figure 3. Competing-Outcomes Analysis of the VentricularAssist Cohorts.
Four mutually exclusive outcome events were tracked for
this analysis: death occurring while the child was receiving circulatory support with the ventricular assist device,
heart transplantation, weaning from the device but either
dying or having an unacceptable neurologic outcome
within 30 days after weaning or before discharge from the
hospital (whichever was longer), and weaning from the
device without death or an unacceptable neurologic outcome in the period defined above. Children who had not
yet had any of these specific outcome events were classified as being alive and receiving circulatory support.
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0

17

0

12

Receiving
Circulatory
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Recovery

NA

5

NA

11

32¶

1

36¶

0

number of children

Received
Transplant

Outcome at 30 Days

6

0

2

0

Weaned
with Poor
Outcome§

10

1

10

1

Died

32 (67)

23 (96)

36 (75)

23 (96)

no. (%)

Success
at 30
Days†

0.007

0.048

P Value

NA

21

NA

21

Received
Transplant

Weaned
with Poor
Outcome§

32¶

1

36¶

0

6

0

2

1

number of children

Weaned
with
Recovery

10

2

10

2

Died

Outcome at End of Circulatory Support

32 (67)

22 (92)

36 (75)

21 (88)

no. (%)

0.021

0.059

Success at
End of
Circulatory
Support‡ P Value

* The days by which no participants were still alive and receiving circulatory support were as follows: 174 days in cohort 1, 21 days in the ECMO group for cohort 1, 192 days in cohort 2,
and 28 days in the ECMO group for cohort 2. NA denotes not available.
† Success at 30 days in the ventricular-assist group was defined as being alive and receiving circulatory support with the device, having undergone transplantation, or having been
weaned from the device with an acceptable neurologic outcome within 30 days after device removal. Success at 30 days in the ECMO group was defined as being alive and receiving
circulatory support with ECMO or having been successfully weaned from ECMO, either owing to transplantation or weaning without death within 30 days after device removal.
‡ Success at the end of device support in the ventricular-assist group was defined as having undergone transplantation or having been weaned from the device with an acceptable neurologic outcome within 30 days after device removal. Success at the end of device support in the ECMO group was defined as weaning from ECMO because of transplantation or recovery.
§ A poor outcome in the ventricular-assist group was defined as death or an unacceptable neurologic outcome within 30 days after weaning or before discharge from the hospital, whichever was longer. A poor outcome in the ECMO group was defined as death within 30 days after weaning from the device; data on neurologic outcomes were unavailable from the ELSO
database.
¶ Data from patients who underwent device explantation and survived for at least 30 days were censored; the ELSO database does not specify whether such explants are due to recovery
or transplantation.
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DISCUSSION
Adults with severe heart failure have benefited
from a series of technological advances in the
use of ventricular assist devices as a bridge to
heart transplantation.14-16 Progress in developing
pediatric devices has been much slower because
of the proportionately greater variation in size
among children. Other reasons for the slow
progress include biologic differences in the response to anticoagulant medicines, low levels of
interest in the medical industry, and in particular, the size constraints in very small babies.
In this trial, we evaluated the use of the Excor
Pediatric ventricular assist device as a bridging
therapy in children who were on waiting lists for
orthotopic heart transplantation. This device is
available in several sizes, so that its use may be
feasible in children of various ages. We compared outcomes in participants who had received a ventricular assist device to those in
propensity-score–matched, historical control
groups of children who received support with
ECMO, the only other option for mechanical
circulatory support that is currently available for
small children. We found that the rate of survival to device explantation (owing to either
transplantation or recovery) was markedly higher with the ventricular assist device than with
ECMO. The outcome comparison was particularly stringent because a successful outcome in
the ventricular-assist group included an acceptable neurologic outcome, which could not be
systematically analyzed in the ECMO group.
As with the use of a ventricular assist device
for circulatory support in adults, serious adverse
events, including bleeding, infection, and stroke,
occurred in a majority of the study participants.
Although the occurrence of stroke is troubling,
the stroke rate in this cohort is similar to that
reported during the use of ventricular assist de-

of

m e dic i n e

vices in children who had a body-surface area
greater than 1.2 m2 and who were treated with
adult-sized ventricular assist devices.17 The sequelae of stroke in this trial did not preclude
eligibility for transplantation in the majority of
participants, and the stroke-related deficits were
generally mild.
An important limitation of this trial is the lack
of randomization. A randomized design was contemplated, but equipoise in the medical community was lacking. The propensity-score–matching
process resulted in an ECMO group that was
statistically similar to the ventricular-assist group.
However, it is plausible that despite propensityscore matching, the children in the ECMO group
were in some respects more ill than those in the
ventricular-assist group. Given that no other
mechanical support device exists for these patients, we believe that children receiving support with ECMO represent the best comparison
group.
In conclusion, we found that a ventricular assist device available in several sizes for use in
children as a bridge to heart transplantation was
associated with a significantly higher rate of
survival, as compared with ECMO. Serious adverse events, including infection, stroke, and
bleeding, occurred in a majority of the study
participants.
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